GSK, Pfiz­er present key dura­bil­i­ty da­ta for RSV shots, as CDC pan­el scru­ti­nizes ri­val vac­cines

GSK and Pfiz­er pro­vid­ed the first looks on Wednes­day at how long-last­ing pro­tec­tion from their res­pi­ra­to­ry syn­cy­tial virus vac­cines could be for old­er adults, pre­sent­ing new clin­i­cal da­ta in front of a Cen­ters for Dis­ease Con­trol and Pre­ven­tion ad­vi­so­ry group.

Both re­vealed clin­i­cal da­ta that gen­er­al­ly showed a sin­gle dose of their vac­cines pro­tect­ing in­to a sec­ond sea­son, al­beit with some lev­el of wan­ing ef­fi­ca­cy, help­ing an­swer a key un­known for the shots. GSK’s da­ta, in par­tic­u­lar, sug­gest­ed a sin­gle dose pro­vides pro­tec­tion through two sea­sons and that a boost­er dose af­ter a year may not pro­vide ad­di­tion­al ben­e­fit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER